FA
ALXN

FDx Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

FDx Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,626
Closed -$254K – 813
2020
Q4 		$254K Buy
+1,626
New +$209K 0.01% 619
2020
Q2 		– Sell
-3,055
Closed -$274K – 637
2020
Q1 		$274K Buy
3,055
+1,048
+52% +$103K 0.02% 406
2019
Q4 		$217K Buy
+2,007
New +$215K 0.01% 572
2018
Q4 		– Sell
-1,623
Closed -$226K – 867
2018
Q3 		$226K Sell
1,623
-792
-33% -$99.3K 0.01% 795
2018
Q2 		$300K Sell
2,415
-7,663
-76% -$896K 0.01% 726
2018
Q1 		$1.12M Sell
10,078
-569
-5% -$68K 0.03% 468
2017
Q4 		$1.27M Buy
10,647
+33
+0.3% +$4.02K 0.03% 467
2017
Q3 		$1.49M Sell
10,614
-668
-6% -$90.8K 0.04% 412
2017
Q2 		$1.37M Buy
11,282
+366
+3% +$42.6K 0.04% 430
2017
Q1 		$1.32M Sell
10,916
-4,720
-30% -$609K 0.04% 427
2016
Q4 		$1.91M Sell
15,636
-582
-4% -$71.2K 0.06% 294
2016
Q3 		$1.99M Buy
16,218
+4,322
+36% +$556K 0.08% 211
2016
Q2 		$1.39M Buy
11,896
+1,994
+20% +$283K 0.06% 276
2016
Q1 		$1.38M Sell
9,902
-621
-6% -$91.2K 0.06% 278
2015
Q4 		$2.01M Buy
10,523
+2,574
+32% +$450K 0.09% 187
2015
Q3 		$1.24M Buy
7,949
+1,432
+22% +$261K 0.11% 195
2015
Q2 		$1.18M Buy
6,517
+4,317
+196% +$745K 0.06% 291
2015
Q1 		$373K Buy
2,200
+41
+2% +$7.42K 0.01% 1109
2014
Q4 		$399K Buy
+2,159
New +$400K 0.02% 626

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FDx Advisors's ALXN Position: Q1 2021 in Review

FDx Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 1,626 shares — an estimated $254K sold.

FDx Advisors first reported a position in ALXN in Q4 2014 and held it in 19 quarters. The position peaked at $2.01M in Q4 2015. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • FDx Advisors reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • FDx Advisors sold 1,626 Alexion Pharmaceuticals shares in Q1 2021, an estimated $254K.
  • FDx Advisors first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 19 quarters.
  • FDx Advisors's Alexion Pharmaceuticals position peaked at $2.01M in Q4 2015.
  • 754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on FDx Advisors's 13F filing for Q1 2021, filed 13 Apr 2021.